+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

A

Actively Recruiting

Researchers are conducting a Phase 3 pediatric clinical trial to study chronic weight management in children and adolescents aged 6 to 17 years who have obesity or are overweight with related health conditions. The study aims to create a master framework that evaluates the safety and effectiveness of medications for these participants. This trial is part of a broader platform trial design with multiple intervention sub-studies ISAs that may start independently as treatments become available. Participants will receive either the study drug orforglipron or a placebo orally, with each intervention sub-study detailing specific treatments. The master protocol sets common entry criteria for all participants across the different sub-studies. Results from the trial will be reported when all intervention sub-studies are completed. During the trial, participants will be monitored from baseline through 72 weeks, with assessments of how many are allocated to each intervention sub-study. Safety and efficacy will be evaluated through ongoing observation and data collection throughout the study period. The trial spans from screening through long-term follow-up, ensuring comprehensive evaluation of the treatments over time.

Age: 6Years - 17YearsAll GendersPhase 3
117 locations
S

Actively Recruiting

Researchers are studying the effects of tirzepatide added to healthy lifestyle changes in children aged 6 to under 12 years who have obesity. This phase 3 trial aims to evaluate how well tirzepatide works, its safety, and how the body processes the drug in this age group. Participants must have obesity defined by a body mass index BMI at or above the 95th percentile for their age and sex and have a history of at least one unsuccessful attempt to lose weight through structured diet and exercise. Participants are randomly assigned to receive either tirzepatide or a placebo, both given as weekly subcutaneous injections. The main treatment period lasts about 104 weeks, during which participants also continue lifestyle interventions. Those who complete this primary phase may have the option to continue receiving tirzepatide treatment for an additional 156 weeks while maintaining lifestyle changes. During the study, participants attend regular visits for assessments including measurements of BMI, body weight, waist circumference, blood pressure, cholesterol, glucose, insulin, liver enzymes, and quality of life questionnaires. Safety monitoring includes evaluating potential side effects and drug levels in the body. Overall participation can last up to about 260 weeks, combining the main treatment and extension periods.

Age: 6Years - 11YearsAll GendersPhase 3
82 locations